Dyax Corp (DYAX) 15.00 $DYAX
Technical Roundup on Biotech Equities - Gilead Sciences, MannKind, ImmunoGen, Dyax, and Pharmacyclics
PR Newswire - Thu Feb 12, 7:45AM CST
Editor Note: For more information about this release, please scroll to bottom.
PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), IMGN: 7.19 (unch), MNKD: 7.00 (+0.02), DYAX: 15.00 (-0.16)
Dyax Corp. to Host Fourth Quarter and Year End 2014 Earnings Call and Webcast
Business Wire - Tue Feb 10, 7:02AM CST
Dyax Corp. (NASDAQ: DYAX) will host a webcast and conference call, including an open question and answer session, Tuesday, February 24, 2015. During the call, management will discuss the Company's financial results for the fourth quarter and full year 2014 as well as progress regarding its key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 15.00 (-0.16)
Shares of DYAX Up 98.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 09, 9:34AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on May 27th, 2014 at $7.59. In approximately 9 months, Dyax has returned 98.42% as of today's recent price of $15.05.
DYAX: 15.00 (-0.16)
Dyax Corp. to Participate in the Leerink Partners 2015 Global Healthcare Conference
Business Wire - Wed Feb 04, 3:15PM CST
Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Leerink Partners 2015 Global Healthcare Conference being held February 11-12, 2015 at the Waldorf Astoria in New York City. The Company is scheduled to present on Wednesday, February 11at 11:05am (ET) and will provide a corporate update on the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 15.00 (-0.16)
Dyax Has Returned 102.8% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Feb 02, 9:09AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on May 27th, 2014 at $7.59. In approximately 8 months, Dyax has returned 102.77% as of today's recent price of $15.38.
DYAX: 15.00 (-0.16)
Looking for a Growth Stock? Why It is Time to Focus on Dyax Corp. (DYAX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 7:49AM CST
Dyax Corp. is one such company that might be well-positioned for future earnings growth as it saw an EPS growth of 10.3% last year and looks great for this year too
DYAX: 15.00 (-0.16)
Will Dyax Corp. (DYAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 8:21AM CST
Will Dyax Corp. (DYAX) Continue to Surge Higher?
DYAX: 15.00 (-0.16)
Uptrend Call Working As Dyax Stock Rises 93.1% (DYAX)
Comtex SmarTrend(R) - Thu Jan 22, 9:35AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on May 27th, 2014 at $7.59. In approximately 8 months, Dyax has returned 93.14% as of today's recent price of $14.65.
DYAX: 15.00 (-0.16)
VBL Therapeutics Announces Ron Cohen and Philip Serlin Nominated to Board of Directors
GlobeNewswire - Tue Jan 20, 7:12AM CST
VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory disease, today announced the nomination of industry veterans Ron Cohen, M.D., and Philip Serlin, C.P.A. to stand for election to the Board of Directors at VBL's extraordinary general meeting of shareholders, scheduled for February 11, 2015. Both individuals currently are leaders of biotechnology companies publicly traded in the US: Dr. Cohen serves as the President and Chief Executive Officer of Acorda Therapeutics, Inc. (Nasdaq:ACOR) and Mr. Serlin is Chief Financial and Operating Officer of BioLineRx Ltd. (Nasdaq:BLRX).
ACOR: 36.14 (-0.51), VBLT: 14.11 (+0.24), DYAX: 15.00 (-0.16), BLRX: 1.87 (-0.02)
Dyax Shares Up 87.3% Since SmarTrend's Buy Recommendation (DYAX)
Comtex SmarTrend(R) - Thu Jan 15, 9:07AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on May 27th, 2014 at $7.59. In approximately 8 months, Dyax has returned 87.34% as of today's recent price of $14.21.
DYAX: 15.00 (-0.16)
LeeAnn Ali Joins BioBridges as Executive Director, Clinical Operations
Marketwired - Tue Jan 13, 7:03AM CST
BioBridges, a leading contract consulting company servicing the pharma, biotech, and medical device industries, proudly announces the addition of LeeAnn Ali to the BioBridges family. Ali brings over 20 years of industry experience to her new role as Executive Director, Clinical Operations.
JNJ: 99.62 (+1.18), CRIS: 3.23 (+0.25), DYAX: 15.00 (-0.16)
Technical Coverage on Biotech Stocks - Arena Pharma, XOMA, Dyax, Mast Therapeutics, and Tekmira Pharma
PR Newswire - Fri Jan 02, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), and Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 31, 2014, the NASDAQ Composite ended at 4,736.05, down 0.87%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 17,823.07, and the S&P 500 closed at 2,058.90, down 1.03%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 791.97, down 0.98%, while the index has advanced 7.03% in the previous three months. Register for your complimentary reports on these five stocks at:
MSTX: 0.47 (+0.01), TKMR: 21.45 (-0.22), ARNA: 4.55 (+0.02), DYAX: 15.00 (-0.16), XOMA: 3.41 (-0.01)
Dyax Has Returned 88.1% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Wed Dec 31, 11:09AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on May 27th, 2014 at $7.59. In approximately 7 months, Dyax has returned 88.13% as of today's recent price of $14.27.
DYAX: 15.00 (-0.16)
Commit To Purchase Dyax Corp At $12.50, Earn 24.9% Annualized Using Options
at The Street - Wed Dec 24, 11:08AM CST
Investors eyeing a purchase of Dyax Corp stock, but tentative about paying the going market price of $14.41/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
DYAX: 15.00 (-0.16)
Uptrend Call Working As Dyax Stock Rises 85.4% (DYAX)
Comtex SmarTrend(R) - Wed Dec 24, 9:35AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on May 27th, 2014 at $7.59. In approximately 7 months, Dyax has returned 85.37% as of today's recent price of $14.06.
DYAX: 15.00 (-0.16)
Can The Uptrend Continue for Dyax (DYAX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:22AM CST
Can The Uptrend Continue for Dyax (DYAX)?
DYAX: 15.00 (-0.16)
How Dyax Corp. (DYAX) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 7:54AM CST
Dyax Corp. is one stock that might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 62
DYAX: 15.00 (-0.16)
Dyax Corp.'s First-in-Human Trial for DX-2930 Conducted by Vince and Associates Clinical Research Featured in the Annals of Allergy, Asthma & Immunology
Business Wire - Thu Dec 18, 7:00AM CST
Vince & Associates Clinical Research, a premier provider of early phase clinical research services to the global biopharmaceutical industry, announced the release of the print publication of scientific data for Dyax Corp.'s (Dyax) DX-2930 monoclonal antibody in a first-in-human study in the Annals of Allergy, Asthma & Immunology.
DYAX: 15.00 (-0.16)
Technical Roundup on Biotech Equities - Gilead Sciences, MannKind, ImmunoGen, Dyax, and Pharmacyclics
PR Newswire - Thu Feb 12, 7:45AM CST
Editor Note: For more information about this release, please scroll to bottom.
PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), IMGN: 7.19 (unch), MNKD: 7.00 (+0.02), DYAX: 15.00 (-0.16)
Dyax Corp. to Host Fourth Quarter and Year End 2014 Earnings Call and Webcast
Business Wire - Tue Feb 10, 7:02AM CST
Dyax Corp. (NASDAQ: DYAX) will host a webcast and conference call, including an open question and answer session, Tuesday, February 24, 2015. During the call, management will discuss the Company's financial results for the fourth quarter and full year 2014 as well as progress regarding its key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 15.00 (-0.16)
Shares of DYAX Up 98.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 09, 9:34AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on May 27th, 2014 at $7.59. In approximately 9 months, Dyax has returned 98.42% as of today's recent price of $15.05. DYAX: 15.00 (-0.16)
Dyax Corp. to Participate in the Leerink Partners 2015 Global Healthcare Conference
Business Wire - Wed Feb 04, 3:15PM CST
Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Leerink Partners 2015 Global Healthcare Conference being held February 11-12, 2015 at the Waldorf Astoria in New York City. The Company is scheduled to present on Wednesday, February 11at 11:05am (ET) and will provide a corporate update on the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 15.00 (-0.16)
Dyax Has Returned 102.8% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Feb 02, 9:09AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on May 27th, 2014 at $7.59. In approximately 8 months, Dyax has returned 102.77% as of today's recent price of $15.38. DYAX: 15.00 (-0.16)
Looking for a Growth Stock? Why It is Time to Focus on Dyax Corp. (DYAX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 7:49AM CST
Dyax Corp. is one such company that might be well-positioned for future earnings growth as it saw an EPS growth of 10.3% last year and looks great for this year too
DYAX: 15.00 (-0.16)
Will Dyax Corp. (DYAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 8:21AM CST
Will Dyax Corp. (DYAX) Continue to Surge Higher?
DYAX: 15.00 (-0.16)
Uptrend Call Working As Dyax Stock Rises 93.1% (DYAX)
Comtex SmarTrend(R) - Thu Jan 22, 9:35AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on May 27th, 2014 at $7.59. In approximately 8 months, Dyax has returned 93.14% as of today's recent price of $14.65. DYAX: 15.00 (-0.16)
VBL Therapeutics Announces Ron Cohen and Philip Serlin Nominated to Board of Directors
GlobeNewswire - Tue Jan 20, 7:12AM CST
VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory disease, today announced the nomination of industry veterans Ron Cohen, M.D., and Philip Serlin, C.P.A. to stand for election to the Board of Directors at VBL's extraordinary general meeting of shareholders, scheduled for February 11, 2015. Both individuals currently are leaders of biotechnology companies publicly traded in the US: Dr. Cohen serves as the President and Chief Executive Officer of Acorda Therapeutics, Inc. (Nasdaq:ACOR) and Mr. Serlin is Chief Financial and Operating Officer of BioLineRx Ltd. (Nasdaq:BLRX).
ACOR: 36.14 (-0.51), VBLT: 14.11 (+0.24), DYAX: 15.00 (-0.16), BLRX: 1.87 (-0.02)
Dyax Shares Up 87.3% Since SmarTrend's Buy Recommendation (DYAX)
Comtex SmarTrend(R) - Thu Jan 15, 9:07AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on May 27th, 2014 at $7.59. In approximately 8 months, Dyax has returned 87.34% as of today's recent price of $14.21. DYAX: 15.00 (-0.16)
LeeAnn Ali Joins BioBridges as Executive Director, Clinical Operations
Marketwired - Tue Jan 13, 7:03AM CST
BioBridges, a leading contract consulting company servicing the pharma, biotech, and medical device industries, proudly announces the addition of LeeAnn Ali to the BioBridges family. Ali brings over 20 years of industry experience to her new role as Executive Director, Clinical Operations.
JNJ: 99.62 (+1.18), CRIS: 3.23 (+0.25), DYAX: 15.00 (-0.16)
Technical Coverage on Biotech Stocks - Arena Pharma, XOMA, Dyax, Mast Therapeutics, and Tekmira Pharma
PR Newswire - Fri Jan 02, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), and Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 31, 2014, the NASDAQ Composite ended at 4,736.05, down 0.87%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 17,823.07, and the S&P 500 closed at 2,058.90, down 1.03%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 791.97, down 0.98%, while the index has advanced 7.03% in the previous three months. Register for your complimentary reports on these five stocks at:
MSTX: 0.47 (+0.01), TKMR: 21.45 (-0.22), ARNA: 4.55 (+0.02), DYAX: 15.00 (-0.16), XOMA: 3.41 (-0.01)
Dyax Has Returned 88.1% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Wed Dec 31, 11:09AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on May 27th, 2014 at $7.59. In approximately 7 months, Dyax has returned 88.13% as of today's recent price of $14.27. DYAX: 15.00 (-0.16)
Commit To Purchase Dyax Corp At $12.50, Earn 24.9% Annualized Using Options
at The Street - Wed Dec 24, 11:08AM CST
Investors eyeing a purchase of Dyax Corp stock, but tentative about paying the going market price of $14.41/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
DYAX: 15.00 (-0.16)
Uptrend Call Working As Dyax Stock Rises 85.4% (DYAX)
Comtex SmarTrend(R) - Wed Dec 24, 9:35AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ
YAX) on May 27th, 2014 at $7.59. In approximately 7 months, Dyax has returned 85.37% as of today's recent price of $14.06. DYAX: 15.00 (-0.16)
Can The Uptrend Continue for Dyax (DYAX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:22AM CST
Can The Uptrend Continue for Dyax (DYAX)?
DYAX: 15.00 (-0.16)
How Dyax Corp. (DYAX) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 7:54AM CST
Dyax Corp. is one stock that might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 62
DYAX: 15.00 (-0.16)
Dyax Corp.'s First-in-Human Trial for DX-2930 Conducted by Vince and Associates Clinical Research Featured in the Annals of Allergy, Asthma & Immunology
Business Wire - Thu Dec 18, 7:00AM CST
Vince & Associates Clinical Research, a premier provider of early phase clinical research services to the global biopharmaceutical industry, announced the release of the print publication of scientific data for Dyax Corp.'s (Dyax) DX-2930 monoclonal antibody in a first-in-human study in the Annals of Allergy, Asthma & Immunology.
DYAX: 15.00 (-0.16)
